Abbott Laboratories (ABT)
NYSE: ABT · Medical Devices · Abbott Park, IL
Our rating: Neutral
Neutral reaffirmed at $113.60, moderate conviction, November 5, 2026.
Breaks if: The Neutral call turns Positive if Abbott reports two consecutive quarters of organic revenue growth above 8% year on year, suggesting an acceleration the current multiple does not fully price in. It turns Cautious if free cash flow margin slips below 14% for two straight quarters — down from the current roughly 16.7% implied by reported figures — signaling that the cash-conversion quality underpinning the thesis is eroding rather than holding.
Key figures
| Market value | $178.4B |
|---|---|
| Revenue, last 12 months | $48.2B |
| Net income, last 12 months | $4.7B |
| Free cash flow, last 12 months | $6.8B |
| Price to earnings | 37.9× |
| Free cash flow yield | 3.8% |
| Dividend yield | 2.4% |
| Operating margin | 13.8% |
| Return on equity | 9.2% |
| Beta to the S&P 500 | 0.17 |
| Volatility, annualized | 24.2% |
Reported quarters
| Quarter ending | Revenue | Year on year | Earnings per share | Free cash flow |
|---|---|---|---|---|
| September 30, 2026 | $13.0B | 14.5% | $0.53 | $1.2B |
| June 30, 2026 | $12.6B | 13.0% | $0.53 | $2.0B |
| March 31, 2026 | $11.2B | 7.8% | $0.61 | $916M |
| December 31, 2025 | $11.5B | 4.4% | $1.02 | $2.6B |
| September 30, 2025 | $11.4B | 6.9% | $0.94 | $2.3B |
| June 30, 2025 | $11.1B | 7.4% | $1.01 | $1.5B |
| March 31, 2025 | $10.4B | 4.0% | $0.76 | $933M |
| December 31, 2024 | $11.0B | 7.2% | $5.26 | $2.1B |
Three-model forecasts for the next quarter
Written November 21, 2026, before the report. Each settles from the SEC filing.
- Revenue for the quarter is at least $12.6B: Claude 82%, Gemini 95%, Mistral 92%
- Diluted earnings per share are at least $1.02: Claude 45%, Gemini 10%, Mistral 58%
- Free cash flow for the quarter is at least $2.63B: Claude 48%, Gemini 25%, Mistral 72%
18 ledger entries and 38 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.